Last reviewed · How we verify

NCT00009815

Phase I Study Of Oral Etoposide In Combination With ORZEL (UFT + Leucovorin) For Advanced Non-Hematological Malignancies

Withdrawn Phase 1 Last updated 18 December 2013
What this trial tests

Phase 1 trial testing etoposide in Unspecified Adult Solid Tumor, Protocol Specific. Withdrawn.

Timeline
1 December 1999

Quick facts

Lead sponsorUniversity of Pittsburgh
PhasePhase 1
StatusWithdrawn
Study typeINTERVENTIONAL
Primary purposetreatment
Start date1 December 1999

Drugs / interventions tested

Conditions studied

Sponsor

University of Pittsburgh

Who can join

18 and older, any sex, with Unspecified Adult Solid Tumor, Protocol Specific. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating patients who have advanced solid tumors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of etoposide

Trials testing the same drug.

Other recruiting trials for Unspecified Adult Solid Tumor, Protocol Specific

Currently open trials in the same condition.

Other University of Pittsburgh trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00009815.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing